NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Stock Has Average Target Price of $34.50 According to Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has earned an average rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $34.50.

A number of equities research analysts recently commented on NRXP shares. UBS Group reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Tuesday, August 25th. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of NRx Pharmaceuticals in a report on Monday, September 14th. Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th.

NRx Pharmaceuticals News Roundup

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: NRx Pharmaceuticals secured a $11.2 million DARPA contract to support a depression trial. The award provides non-dilutive funding for development of the company’s treatment program and may reduce near-term financing pressure. NRx secures DARPA contract for depression trial and $11.2 million award
• Neutral Sentiment: An analyst comparison examined NRx Pharmaceuticals alongside AstraZeneca, but the report provides no specific change to NRXP’s valuation, rating, or operating outlook. AstraZeneca and NRx Pharmaceuticals head-to-head review
• Negative Sentiment: Ascendiant Capital Markets lowered its earnings expectations across multiple periods. Its FY2026 EPS forecast fell to $(0.80) from $(0.36), while its FY2027 forecast dropped to $(0.35) from $0.50. Quarterly estimates were also reduced, including Q3 2026 to $(0.15) from $(0.08), Q4 2026 to $(0.17) from $(0.03), and Q2 2027 to $(0.13) from $0.05.
• Negative Sentiment: The analyst also cut its Q3 2027 estimate to $(0.10) from $0.17 and Q4 2027 to $0.05 from $0.28. The revisions indicate weaker-than-expected earnings prospects and could weigh on NRXP, particularly because the company remains loss-making and has historically reported limited revenue. Q3 EPS estimate for NRx Pharmaceuticals lowered by analyst

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $2.94 on Friday. NRx Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $5.05. The stock has a market cap of $127.30 million, a PE ratio of -5.35 and a beta of 2.07. The firm’s 50 day moving average price is $3.29 and its two-hundred day moving average price is $3.33.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The business had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.33 million. As a group, sell-side analysts predict that NRx Pharmaceuticals will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently bought and sold shares of NRXP. AdvisorShares Investments LLC raised its holdings in NRx Pharmaceuticals by 28.2% in the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after purchasing an additional 92,463 shares during the period. Ethos Financial Group LLC grew its holdings in shares of NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after buying an additional 4,000 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of NRx Pharmaceuticals in the 2nd quarter valued at $54,000. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company’s programs are investigational and are intended to address areas where available therapies may have limitations.

NRx’s lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior.